Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries
- 14 August 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (7) , 820-825
- https://doi.org/10.1161/hc3301.092790
Abstract
Background Prostanoid synthesis via the action of cyclooxygenase-2 (COX-2) is a component of the inflammatory response. Prostacyclin, a product of COX-2 in vascular endothelium, has important physiological roles, such as increasing blood flow to injured tissues, reducing leukocyte adherence, and inhibiting platelet aggregation. We examined the possibility that selective COX-2 inhibition could suppress the protective effects of prostacyclin, resulting in an alteration of the hemostatic balance and vascular tone. Methods and Results Circumflex coronary artery thrombosis was induced in dogs by vascular electrolytic injury. Orally administered celecoxib (COX-2 inhibition) or high-dose aspirin (HDA) (COX-1 and COX-2 inhibition) did not alter time to occlusive thrombus formation compared with controls (celecoxib 77.7±7.2 minutes, HDA 72.0±18.5 minutes, control 93.0±21.8 minutes). Oral HDA with an endothelial recovery period (HDA-ER) (COX-1 inhibition) produced a significant increase in time to vessel occlusion (257.0±41.6 minutes). The observed increase in time to occlusion was abolished when celecoxib was administered to animals dosed with HDA-ER (80.7±20.6 minutes). The vasomotor effect of endothelium-derived prostacyclin was examined by monitoring coronary flow during intracoronary administration of arachidonic acid or acetylcholine. In celecoxib-treated animals, vasodilation in response to arachidonic acid was reduced significantly compared with controls. Conclusions The results indicate important physiological roles for COX-2–derived prostacyclin and raise concerns regarding an increased risk of acute vascular events in patients receiving COX-2 inhibitors. The risk may be increased in individuals with underlying inflammatory disorders, including coronary artery disease.Keywords
This publication has 20 references indexed in Scilit:
- NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesionsPublished by Elsevier ,2002
- Selective cyclo‐oxygenase‐2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherenceBritish Journal of Pharmacology, 2000
- Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic LesionsThe American Journal of Pathology, 1999
- Eicosanoids and the gastrointestinal tractGastroenterology, 1995
- Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.Journal of Clinical Investigation, 1994
- The utility of excitatory amino acid (EAA) antagonists as analgesic agents. I. Comparison of the antinociceptive activity of various classes of EAA antagonists in mechanical, thermal and chemical nociceptive testsPain, 1994
- High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injuryJournal of the American College of Cardiology, 1993
- Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.Journal of Clinical Investigation, 1990
- Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary arteryBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1989
- The endothelial cell as a metabolic and endocrine organTrends in Pharmacological Sciences, 1987